Valuation: Eisai Co., Ltd.

Market Cap 1,424B 9.04B 8.1B 7.45B 6.75B 12.61B 858B 12.85B 88.82B 35.66B 452B 33.93B 33.21B P/E 2027 *
24.8x
P/E 2028 * 20.9x
Enterprise Value 1,340B 8.51B 7.62B 7.01B 6.35B 11.87B 808B 12.09B 83.57B 33.55B 425B 31.92B 31.24B EV / Sales 2027 *
1.47x
EV / Sales 2028 * 1.37x
Free-Float
94.68%
Yield 2027 *
3.24%
Yield 2028 * 3.2%
1 day+1.57%
1 week-0.47%
1 month+4.06%
3 months+4.64%
6 months+7.79%
Current year+8.41%
1 week 4,920
Extreme 4920
5,168
1 month 4,571
Extreme 4571
5,192
Current year 3,660
Extreme 3660
5,243
1 year 3,660
Extreme 3660
5,243
3 years 3,463
Extreme 3463
8,267
5 years 3,463
Extreme 3463
11,250
10 years 3,463
Extreme 3463
12,765
Manager TitleAgeSince
Chief Executive Officer 78 2003-05-31
Director of Finance/CFO 49 2025-12-31
Chief Tech/Sci/R&D Officer 58 2023-03-31
Director TitleAgeSince
Director/Board Member 78 1983-05-31
Director/Board Member 67 2024-06-13
Director/Board Member 68 2025-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%-0.47%+10.55%-36.54% 9.04B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +2.03%+5.26%+42.98%+72.45% 427.1B
Weighted average by Cap. +2.01%+6.58%+50.42%+100.15%

Financials

2027 *2028 *
Net sales 914B 5.8B 5.2B 4.78B 4.33B 8.1B 551B 8.25B 57.03B 22.89B 290B 21.78B 21.32B 972B 6.17B 5.53B 5.08B 4.61B 8.61B 586B 8.77B 60.62B 24.33B 308B 23.16B 22.66B
Net income 57.94B 368M 329M 303M 275M 513M 34.92B 523M 3.61B 1.45B 18.37B 1.38B 1.35B 68.25B 433M 388M 357M 323M 605M 41.14B 616M 4.26B 1.71B 21.64B 1.63B 1.59B
Net Debt -84.27B -535M -479M -441M -399M -746M -50.8B -760M -5.26B -2.11B -26.72B -2.01B -1.97B -94.04B -597M -535M -492M -446M -833M -56.69B -849M -5.87B -2.35B -29.82B -2.24B -2.19B
Projected Income Statement - Annual - Eisai Co., Ltd.
Logo Eisai Co., Ltd.
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Employees
10,543
Date Price Change Volume
26-10-30 JP¥5,052.00 +1.57% 1,344,000
26-10-29 JP¥4,974.00 -1.87% 2,177,500
26-10-28 JP¥5,069.00 -0.65% 1,070,500
26-10-27 JP¥5,102.00 +0.08% 1,134,000
26-10-26 JP¥5,098.00 +0.43% 983,800
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Eisai Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
5,052.00JPY
Average target price
4,603.57JPY
Spread / Average Target
-8.88%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Eisai Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 4523 Stock